Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
Latest Jobs
Exclusive vacancies may not be shown here, please contact Natasha on +44 1494 818 053 or for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Natasha Wilson
Executive Recruiter
+44 1494 818 053

I cannot thank the Contractor Manager enough for the support that they have given me since working for Zenopa.
Lynne, 2012

Astellas award winners make prostate cancer breakthrough

20 August 2013 11:11 in Pharmaceutical Company Product News

Astellas award winners make prostate cancer breakthroughAstellas has announced that a team which recently won its Astellas European Foundation Urology Prize Fund Award has made a key breakthrough in prostate cancer research.

Scientists at France's Institut Bergonie have achieved their goal of identifying new gene targets for use in the development of alternative strategies to treat prostate cancer, just four years after receiving the Astellas award.

Led by Dr Nadine Houede, the researchers found that six specific genes may play an important role in the sensitivity of high-grade prostate tumours to platinum derivative-based anti-cancer drugs.

Astellas' funding was essential in helping the team to obtain a proof of concept for this research.

Ken Jones, trustee of the Astellas European Foundation and president and chief executive officer of Astellas Pharma Europe, said: "This type of scientific research is absolutely vital ... and enabling scientists from across Europe to make progress in this work is exactly what the awards were set up to do."

This comes after the firm announced the appointment of Dr Claire Thom as its new senior vice-president for global oncology development earlier this month.ADNFCR-8000103-ID-801627083-ADNFCR

Other news stories from 20/08/2013

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency

© Copyright 2015 Zenopa Ltd